Main results
One small, short-term trial was eligible for inclusion. We included this study of 25 adults with chronic lung disease (including bronchiectasis) as the other conditions were linked to development of bronchiectasis and all had chronic sputum production.
The single trial in adults reported a significant reduction in sputum production over 14 days in the treatment group (inhaled indomethacin) compared to placebo (difference -75.00 g/day; 95% ) and a significant improvement in a dyspnoea score (difference -1.90; 95% CI -3.15 to -0.65). There was no significant difference between groups in lung function or blood indices. No adverse events were reported.
Authors' conclusions
There is currently insufficient evidence to support or refute the use of inhaled NSAIDs in the management of bronchiectasis in adults or children. One small trial reported a reduction in sputum production and improved dyspnoea in adults with chronic lung disease who were treated with inhaled indomethacin, indicating that further studies on the efficacy of NSAIDs in treating patients with bronchiectasis are warranted.
P L A I N L A N G U A G E S U M M A R Y

Inhaled non-steroid anti-inflammatories (NSAIDs) for children and adults with bronchiectasis
The airways of patients with bronchiectasis are characterised by chronic inflammation. The anti-inflammatory effects of inhaled nonsteroid anti-inflammatory drugs (NSAIDs) may be beneficial in patients with bronchiectasis. However, the short and long-term benefits in both adults and children require investigation, in addition to the potential side effects of the long-term use of NSAIDs. For this review we found one small study that reported an improvement in sputum production and dyspnoea (shortness of breath) in adults with chronic lung disease (chronic bronchitis, bronchiectasis or diffuse panbronchiolitis) who received inhaled indomethacin compared to the placebo group. There was no significant improvement in lung function (forced expiratory volume in one second (FEV 1 ) and vital capacity (VC)). However, the small scale of this study and the collective analysis of data from the three disease states made it difficult to draw any solid conclusions on the benefit of using NSAIDs to treat adults with bronchiectasis. There were no studies identified on the use of NSAIDs in children with bronchiectasis.
B A C K G R O U N D Description of the condition
Bronchiectasis, previously termed an 'orphan disease', is increasingly recognised as a major cause of respiratory morbidity, especially in developing countries (Karadag 2005; Karakoc 2001 ) and in pockets of affluent countries (Chang 2008) . The underlying aetiology of bronchiectasis varies; it may follow recurrent respiratory infections or be secondary to rare immune deficiencies. However, bronchiectasis is also a common pathway for a variety of diseases. Thus, the presence of bronchiectasis is also increasingly recognised in common (e.g. chronic obstructive pulmonary disease (COPD) (O'Brien 2000) and uncommon respiratory diseases (e.g. bronchiolitis obliterans and sarcoidosis (Lewis 2002)) as well as non-primary respiratory (e.g. autoimmune) diseases. When bronchiectasis is present with another underlying disorder, it increases the morbidity and mortality of the underlying disease (Keistinen 1997; Lewis 2002) . For example, in diseases such as COPD the presence of bronchiectasis has been reported in 29% to 50% (O'Brien 2000) of cohorts and when present increases the severity and frequency (Gursel 2006) of respiratory exacerbations. The dominant symptoms and signs of bronchiectasis are productive or wet cough, dyspnoea on exertion and presence of other respiratory signs (clubbing, chest wall deformity, respiratory noises such as wheeze or crepitations on auscultation). In the long term pulmonary decline may occur (Keistinen 1997). Also, as in patients with COPD, children and adults with bronchiectasis also suffer from recurrent acute exacerbations, some of which require hospitalised treatment (Chang 2008) . Effective management regimes for bronchiectasis improve quality of life (Courtney 2008; Martinez-Gracia 2005; Muthalithas 2008) , and could reduce the frequency or severity of respiratory exacerbations (Cymbala 2005) and/or the long-term pulmonary decline (Chang 2008) . Thus, management of the symptoms and severity of bronchiectasis is important.
Description of the intervention
Non-steroid anti-inflammatory drugs (NSAIDs) are a class of medication that act as non-selective inhibitors of the enzyme cyclooxygenase, inhibiting both the cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) isoenzymes. Non-steroidal antiinflammatories have analgesic, antipyretic and anti-inflammatory effects and reduce pain, fever and inflammation. NSAIDs are usually given orally but the inhaled formulation has been also used in people with bronchorrhoea, a feature present in many patients with bronchiectasis (Tamaoki 1992) . A Cochrane Review of oral NSAIDs for people with bronchiectasis did not find any suitable randomised controlled trials (Kapur 2007) .
How the intervention might work
Based on Cole's 'vicious circle hypothesis', microbial colonisation/ infection is important in the pathophysiology of bronchiectasis as it leads to bronchial obstruction and an abnormal or exaggerated inflammatory response (Cole 1986). Anti-inflammatory drugs may reduce the inflammatory cascade and thus ameliorate symptoms and reduce long-term pulmonary decline. As the airways of patients with bronchiectasis have intense neutrophilic inflammation (Cole 1986), the anti-inflammatory effect of NSAIDs may have a beneficial effect for patients with bronchiectasis. "Blockade of cyclooxygenase pathway with indomethacin could decrease respiratory tract fluid and mucus by inhibiting chloride secretion and glandular secretion and by enhancing Na absorption across airway mucosa" (Tamaoki 1992) . Animal studies have shown that pre-treatment with inhaled indomethacin protects the airway from distilled water and ozone which increases lung resistance through swelling of airway epithelial cells (Mochizuki 2002) .
Why it is important to do this review
Although NSAIDs may have potential benefits for those with bronchiectasis, oral NSAIDs are associated with a number of adverse events, particularly of the gastrointestinal tract (Behrman 2003) . NSAIDs may be better tolerated when inhaled, however transient upper airway irritation has been reported (Ong 2004; Sestini 1999) . It is therefore important to assess any additional side affects associated with the inhalation of NSAIDs. In cystic fibrosis (CF), preliminary evidence suggests that NSAIDs may prevent pulmonary deterioration in people with mild lung disease due to CF (Lands 2007). However, extrapolation of treatment for CF to non-CF bronchiectases may be harmful (e.g. recombinant human DNase efficacious in CF causes harm in non-CF bronchiectasis (Crockett 2001)). Thus, a systematic review on the efficacy of inhaled NSAIDs in the management of children and adults with bronchiectasis would help guide clinical practice.
O B J E C T I V E S
To evaluate the efficacy of inhaled NSAIDs in children and adults with bronchiectasis:
(a) during stable bronchiectasis; and for reducing:
(b) the severity and frequency of acute respiratory exacerbations; and (c) long-term pulmonary decline.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised controlled trials (RCTs) comparing inhaled NSAIDs to a control group (placebo or usual treatment) in patients with bronchiectasis
Types of participants
Children or adults with bronchiectasis (defined clinically or radiologically) not related to cystic fibrosis. We excluded participants with cystic fibrosis or with other diseases where bronchiectasis was not present.
Types of interventions
All types of inhaled NSAIDs.
Types of outcome measures Primary outcomes
We planned to obtain data on at least one of the following outcome measures. 
Search methods for identification of studies Electronic searches
We used the following topic search strategy to identify the relevant randomised controlled trials listed in the electronic databases: ("bronchiectasis" OR "suppurative lung disease" as (textword) or (MeSH )) AND ("inhaled" OR "nebulise" OR "nebulised" as (textword) or (MeSH )) AND ("anti-inflammatory" OR "diclofenac" OR "etodolac" OR "ketorolac" OR "sulindac" OR "tolmentin" OR "diflunisal" OR "salsalate" OR "meloxicam" OR "piroxicam" OR "flurbiprofen" OR "Ibupropen" OR "ketoprofen" OR "naproxen" OR "oxaprozin" OR "indomethacin" OR "COX2 inhibitors" OR "celecoxib" OR "rofecoxib" OR "valdecoxib") as (textword) or (MeSH) We identified trials from the following sources:
1. 
Searching other resources
We also searched the references in relevant publications. We planned to communicate with the authors of trials included in the review, if necessary.
Data collection and analysis
Selection of studies
From the title, abstract or descriptors, two authors (SP, AC) independently reviewed the literature searches to identify potentially relevant trials for full review. We conducted searches of bibliographies and texts to identify additional studies. From the full text and using the specified criteria, the same two authors independently selected trials for inclusion. We planned to resolve any disagreement by third party adjudication (JU).
Data extraction and management
We reviewed trials that satisfied the inclusion criteria for the following information: study setting; year of study; source of funding; patient recruitment details (including number of eligible subjects); inclusion and exclusion criteria; other symptoms; randomisation and allocation concealment method; numbers of participants randomised; blinding (masking) of participants, care providers and outcome assessors; dose and type of intervention; duration of therapy; co-interventions; numbers of patients not followed up; reasons for withdrawals from study protocol (clinical, side effects, refusal and other); details on side effects of therapy; and whether intention-to-treat analyses were used where possible. We would have extracted data on the outcomes described previously. Where required we planned to obtain further information from the authors.
Assessment of risk of bias in included studies
In order to assess the risk of bias, two review authors (SP, AC) independently assessed the quality of the studies according to the criteria described by Jüni (Jüni 2001).
Allocation concealment
We assessed allocation concealment as follows. 1. Adequate: if the allocation of participants involved a central independent unit, on-site locked computer, identically appearing numbered drug bottles or containers prepared by an independent pharmacist or investigator, or sealed opaque envelopes.
2. Unclear: if the method used to conceal the allocation was not described.
3. Inadequate: if the allocation sequence was known to the investigators who assigned participants or if the study was quasirandomised.
Generation of the allocation sequence
Each study was to be graded for allocation concealment as follows.
1. Adequate: if methods of randomisation included using a random number table, computer-generated lists or similar methods.
2. Unclear: if the trial was described as randomised, but no description of the methods used to allocate participants to treatment group was described.
3. Inadequate: if methods of randomisation included alternation, the use of case record numbers, dates of birth or day of the week, and any procedure that was entirely transparent before allocation.
Blinding (or masking)
Each study was graded for blinding as follows.
1. Blinding of clinician (person delivering treatment) to treatment allocation.
2. Blinding of participant to treatment allocation. 3. Blinding of outcome assessor to treatment allocation.
Follow up
Each study was graded as to whether numbers of and reasons for drop-outs and withdrawals in all intervention groups were described, or if it was specified that there were no drop-outs or withdrawals.
Dealing with missing data
The authors planned to request further information from the primary investigators where required but as the only included study was published in 1992, we did not contact the authors (Tamaoki 1992)
Assessment of heterogeneity
We planned to describe any heterogeneity between the study results and test this to see if it reached statistical significance using the Chi 2 test. We would have considered heterogeneity to be significant if the P value was less than 0.10 (Higgins 2008). We also planned to use the I 2 statistic, where heterogeneity is categorised such that a value of under 25% is considered low, around 50% is considered moderate and over 75% is considered a high degree of heterogeneity (Higgins 2003) .
Assessment of reporting biases
If meta-analysis had been possible, we would have assessed publication bias using a funnel plot. We intended to investigate and report on any selective reporting.
Data synthesis
For the dichotomous outcome variables of each individual study, we would have calculated the odds ratios (OR) using a modified intention-to-treat analysis. This analysis assumes that children not available for outcome assessment have not improved (and probably represents a conservative estimate of effect). An initial qualitative comparison of all the individually analysed studies examines whether pooling of results (meta-analysis) is reasonable. This would take into account differences in study populations, inclusion/exclusion criteria, interventions, outcome assessment and estimated effect size.
The results from studies that met the inclusion criteria and reported any of the outcomes of interest were to be included in the subsequent meta-analyses. We planned to calculate the summary weighted odds ratio and 95% confidence interval (CI) (fixed-effect model) (Cochrane statistical package, RevMan version 5 (RevMan 2008)). We would only have combined data from parallel studies. We planned to calculate numbers needed to treat (NNT) from the pooled OR and its 95% CI applied to a specified baseline risk using an online calculator (Cates 2003) . If studies reported outcomes using different measurement scales, we planned to estimate the standardised mean difference (SMD). We would have described and explored any heterogeneity between the study results. We would have included the 95% CI estimated using a random-effects model whenever there were concerns about statistical heterogeneity.
Subgroup analysis and investigation of heterogeneity
The following a priori subgroup analyses were planned: 1. children (aged 18 years or less) and adults (> 18 years); 2. severity of bronchiectasis (based on FEV 1 : > 80% classified as mild, 50% to 79% classified as moderate, 30% to 49% classified as severe, < 30% classified as very severe).
Sensitivity analysis
We also planned sensitivity analyses to assess the impact of the potentially important factors on the overall outcomes:
• variation in the inclusion criteria;
• differences in the medications used in the intervention and comparison groups;
• differences in outcome measures;
• analysis using random-effects model;
• analysis by treatment received; and • analysis by intention-to-treat.
R E S U L T S Description of studies
See: Characteristics of included studies; Characteristics of excluded studies. See the 'Characteristics of included studies' and 'Characteristics of excluded studies' tables.
Results of the search
The Airways Group specialised register/literature search performed in Oct 2008 and October 2009 yielded 173 (153 and 20 respectively) references. There were no RCTs which focused specifically on adults or children with bronchiectasis. We identified two publications which were considered for inclusion in this review. One study Tamaoki 1992 was included; the second (Llewellyn-Jones 1995) did not meet the eligibility criteria and was excluded.
Included studies
There were no studies identified which focused solely on bronchiectasis in either adults or children. However a single, small study on adults with chronic lung disease, including bronchiectasis, was included in this review as the additional two chronic lung disease conditions in the study lead to bronchiectasis, and bronchorrhoea is a key clinical feature of bronchiectasis. The detail of this study is described in the 'Characteristics of included studies' table. Tamaoki and colleagues (Tamaoki 1992) examined the short-term effect (14 days) of inhaled indomethacin on sputum and blood indices, dyspnoea scale and lung function in 25 adults with chronic lung disease (eight with bronchiectasis, 12 with chronic bronchitis and five with diffuse panbronchiolitis).
Excluded studies
We excluded one study (Llewellyn-Jones 1995) as it was not a randomised controlled trial.
Risk of bias in included studies
Allocation
The method used for allocating treatment groups was not described.
Blinding
The patients and investigators responsible for disease follow up and data analysis were blinded. The doctor responsible for allocating treatment groups was not blinded but was not involved in follow up or data analysis.
Incomplete outcome data
Data were complete for all participants. However, data analysis did not distinguish bronchiectasis patients from the other respiratory groups, other than that for sputum production.
Selective reporting
We identified no selective reporting bias in the study.
Other potential sources of bias
We identified no other potential sources of bias.
Effects of interventions
The one study included in this review evaluated the effect of inhaled indomethacin on sputum production, quality of life and lung function in 25 patients with chronic lung disease, including eight patients with bronchiectasis.
Respiratory symptoms
The only clinical data reported were in the form of the Borg score, which showed a significant difference between groups (difference of -1.90; 95% CI -3.15 to -0.65) (Analysis 1.1). (The minimum clinically important difference (in COPD) is 1 unit (Ries 2005)). Days with respiratory symptoms (our primary outcome measure) was not reported in the study.
Lung function
There was no significant difference between groups for FEV 1 % predicted (difference between groups of -2.90%; 95% CI -13.30 to 7.50) or for vital capacity (VC) % predicted (difference -2.90%; 95% CI -10.58 to 4.78) (Analysis 2.1 and Analysis 2.2).
Other indices
For sputum indices (Analysis 3.2), a significant decrease in sputum production in the indomethacin group was found compared with the placebo group (difference -75.00 g/day; 95% CI -134.61 to -15.39) but there was no difference in the density of bacteria per gram of sputum (difference -0.30; 95% CI -1.71 to 1.11). For blood indices (Analysis 3.3) no significant difference between groups was found for either erythrocyte sedimentation rate (ESR) (difference -2.00 mm/hr; 95% CI -13.42 to 9.42) or total white cell count (difference -400.00 cells/ml; 95% CI -1654.94 to 854.94).
Adverse events
No adverse events were reported in the study.
D I S C U S S I O N Summary of main results
Data from one small, short-term (14-day) study of 25 adults with chronic lung disease (12 with chronic bronchitis, eight with bronchiectasis and five with panbronchiolitis) suggest that inhaled indomethacin (a type of NSAID) was significantly beneficial in reducing sputum production and improving dyspnoea compared to placebo. The clinically important difference for the Borg scale in bronchiectasis is unknown but that for COPD is 1 unit (Ries 2005) and thus the difference between groups for dyspnoea (-1.90; 95% CI -3.15 to -0.65) is likely to be clinically important. There was no difference between groups for lung function or blood indices.
Overall completeness and applicability of evidence
The small study and limited number of patients with bronchiectasis in the sole included study limits any definitive conclusion. We included this study on the same basis for inclusion as a study in the Cochrane Review of pneumococcal vaccination for bronchiectasis (Chang 2009) . No randomised controlled trials of inhaled NSAIDs in children with bronchiectasis were identified.
Quality of the evidence
The sole included study in this review (Tamaoki 1992) was a double-blind, randomised study but the sample size was small and allocation concealment remains unknown. Data from the three disease states were described and analysed collectively, thus bronchiectasis-specific data are unknown. Data were expressed as means +/-SEM (standard error of the mean). Two-way analysis of variance and Student's paired t test were used for normally distributed variables. The Newman-Keuls test was used for multiple comparisons. A P value of less than 0.05 was considered statistically significant.
Agreements and disagreements with other studies or reviews
The Cochrane Review of oral NSAIDs for cystic fibrosis concluded that NSAIDs are likely to slow the progression of lung disease (Lands 2007). Data on sputum production or dyspnoea were not reported in the review. The Cochrane Review of oral NSAIDs for bronchiectasis (Kapur 2007) did not find any relevant studies.
A U T H O R S ' C O N C L U S I O N S
Implications for practice
Although a single study has shown some benefit in the short-term use of inhaled indomethacin in adults with chronic lung disease (including bronchiectasis and those at risk of bronchiectasis), there is currently insufficient evidence to support or refute the use of inhaled NSAIDs in children or adults with bronchiectasis. NSAIDs may be beneficial in the immediate term in reducing sputum production and therefore improving quality of life in adults with chronic lung disease. However, there were too few bronchiectasis patients included in the study group and the duration of treatment was too short to provide adequate information on the beneficial or adverse effects of inhaled NSAIDs in adults with bronchiectasis. There is no data currently available on the effectiveness of inhaled NSAIDs in children with bronchiectasis.
Implications for research
The data presented in the one study included in this review indicate that a double-blind, randomised, placebo-controlled trial is warranted to investigate the short-term (< 12 months) and long-term (> 12 months) beneficial and adverse effects of inhaled NSAIDs in both adults and children with bronchiectasis. Randomised controlled trials should investigate children and adults separately and include data as highlighted in the 'Types of outcome measures' section of this review.
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C H A R A C T E R I S T I C S O F S T U D I E S Characteristics of included studies [ordered by study ID]
Tamaoki 1992
Methods Double-blind, randomised, placebo-controlled trial Pulmonary function was assessed by a change in vital capacity (VC) and FEV 1 pre-treatment (day 0) and on day 14. Quality of life was assessed by Borg's ratio scale to questions related to breathlessness and dyspnoea Sputum was analysed for change in production (g/day), cyclooxygenase products (PGE 2, PGF 2a , 6-oxo-PGF 1a , TxB 2 ) and microbiological culture Statistical analysis: data were expressed as means +/-SEM. Two-way analysis of variance and Student's paired t test were used for normally distributed variables. The Newman-Keuls test was used for multiple comparisons. A P value of less than 0.05 was considered statistically significant Participants 25 adults (age 29 to 78 years) diagnosed with chronic lung disease (chronic bronchitis, diffuse panbronchiolitis or bronchiectasis) and bronchorrhoea of at least 4 weeks. Eight of the 25 participants had bronchiectasis but all had symptoms of bronchiectasis and 21 had chronic colonisation with respiratory pathogens present in adults with bronchiectasis -17 had Pseudomonas aeruginosa, 3 with Haemophilus influenzae and one with Staphylococcus aureus. Of the 8 subjects with bronchiectasis, 4 were allocated to the indomethacin group and 4 to the placebo group. All had no history of respiratory allergy Interventions Treatment group 1: inhaled indomethacin, 2 ml aerosol preparation of 1.2 µg/ml in saline 3 times daily for 14 days Treatment group 2: inhaled placebo, 2 ml aerosolised saline alone 3 times daily for 14 days Method of delivery: nebuliser delivering aerosolised particles with a median particle diameter of 4. 5 to 5 µm Outcomes Data for all 3 disease states were analysed collectively. Outcomes were sputum indices (% solid composition, sputum bacterial density and inflammatory markers -prostaglandin E2, PGF 2a , 6-oxo-PGF 1a , TxB 2 ), Borg score ratio scale for breathlessness and dyspnoea, white cell count (WCC) , erythrocyte sedimentation rate (ESR) and spirometry The only outcome for which results were reported separately for bronchiectasis patients was effect on sputum production Notes We elected to include all outcomes as although not all had the diagnosis of bronchiectasis, the additional 2 diseases (chronic bronchitis and panbronchiolitis) overlap with bronchiectasis and can eventually lead to bronchiectasis. Furthermore, the high number colonised with bacteria especially with Pseudomonas indicates that bronchiectasis would have been likely to be present if a multidetector high resolution CT scan was performed in all subjects
Risk of bias
Item
Authors' judgement Description
Adequate sequence generation? Unclear Not described 
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